Table 2.
Results of clinical trials for new agents targeting co-stimulatory molecules on T cells and cellular therapy.
| Trial name/code | Setting | Phase | Molecule | N° of NSCLC patients | ORR (CR) | DCR | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|---|
| NCT02315066 | Pretreated with ICIs | I | PF-8600 (OX40 agonist) + utomilumab (CD137 agonist) | 20 | 5% | 40% | – | – |
| QUILT 3.055 (NCT03228667) | Pretreated with ICIs | II | N803 (IL-15 superagonist + ICI) | 81 | 8% | 59% | 3,9 mo | 13,8 mo |
| NCT03215810 | Pretreated with ICIs | I | TILs | 13 | 46% | 92% | – | – |
| NCT03987867 | First line | I | CIK cells + chemotherapy + Sintilimab (anti-PD-1) | 32 | 81,3% | 100% | 6 mo-PFS 84,4% | – |
| Atalante (NCT02654587) |
Pretreated with ICI and platinum chemo | III random | OSE2101 (anticancer vaccine) vs docetaxel/pemetrexed | 118 pts PoI | 8% vs 18% | 6-mo DCR 26% vs 25% | 2,7 vs 3,4 mo | 11,1 vs 7,5 mo p=0,02 |